Dosing in neonates: Special considerations in physiology and trial design

Pediatric Research

Volumn 77, Issue 1, 2015, Pages 2-9

  Ku, Lawrence C ^a   Brian Smith, P ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; FLUCONAZOLE; MICAFUNGIN; DRUG;

ANALYTIC METHOD; CLINICAL TRIAL (TOPIC); DRIED BLOOD SPOT TESTING; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; HUMAN; NEWBORN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SAMPLING; STUDY DESIGN; ANIMAL; CHEMISTRY; DOSE CALCULATION; DRUG DESIGN; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; METHODOLOGY; PEDIATRICS; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DOSAGE CALCULATIONS; FLUCONAZOLE; GLOMERULAR FILTRATION RATE; HUMANS; INFANT, NEWBORN; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84927927121     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2014.143     Document Type: Review

References (80)

1. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther 2012;91:796-801
2. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67
3. Laughon MM, Benjamin DK Jr, Capparelli EV, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 2011;4:643-52
4. Zajicek A. The National Institutes of Health and the Best Pharmaceuticals for Children Act. Paediatr Drugs 2009;11:45-7
5. Laughon MM, Avant D, Tripathi N, et al. Drug labeling and exposure in neonates. JAMA Pediatr 2014;168:130-6
6. Mooij MG, Schwarz UI, de Koning BA, et al. Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. Drug Metab Dispos 2014;42:1268-74
7. Smits A, Annaert P, Allegaert K. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. Int J Pharm 2013;452:8-13
8. van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb Exp Pharmacol 2011;205:51-75
9. Mulla H. Understanding developmental pharmacodynamics: importance for drug development and clinical practice. Paediatr Drugs 2010;12: 223-33
10. Tayman C, Rayyan M, Allegaert K. Neonatal pharmacology: extensive interindividual variability despite limited size. J Pediatr Pharmacol Ther 2011;16:170-84
11. Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and children. Pediatr Rev 1998;19:423-8
12. Koren G. Therapeutic drug monitoring principles in the neonate. National Academy of CLinical Biochemistry. Clin Chem 1997;43:222-7
13. Skinner AV. Neonatal pharmacology. Anaesth Intensive Care Med 2011;12:79-84
14. Visscher M, Narendran V. The Ontogeny of Skin. Adv Wound Care (New Rochelle) 2014;3:291-303
15. Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 2000;106:Suppl 3:S128-38
16. Tom-Revzon C. Erratic absorption of intramuscular antimicrobial delivery in infants and children. Expert Opin Drug Metab Toxicol 2007;3:733-40
17. American Academy of Pediatrics, Committee on Drugs. Alternative routes of drug administration-advantages and disadvantages (subject review). Pediatrics 1997;100:143-52
18. Allegaert K, Verbesselt R, Naulaers G, et al. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 2008;63:16-24
19. Warner A. Drug use in the neonate: interrelationships of pharmacokinetics, toxicity, and biochemical maturity. Clin Chem 1986;32:721-7
20. Lorenz JM, Kleinman LI, Ahmed G, Markarian K. Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. Pediatrics 1995;96(3 Pt 1):484-9
21. Watt KM, Benjamin DK Jr, Cheifetz IM, et al. Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J 2012;31:1042-7
22. Aranda JV, Sitar DS, Parsons WD, Loughnan PM, Neims AH. Pharmacokinetic aspects of theophylline in premature newborns. N Engl J Med 1976;295:413-6
23. Routledge PA. Pharmacokinetics in children. J Antimicrob Chemother 1994;34:Suppl A:19-24
24. Seyberth HW, Kauffman RE. Basics and dynamics of neonatal and pediatric pharmacology. Handb Exp Pharmacol 2011;205:3-49
25. Strazielle N, Ghersi-Egea JF. Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharm 2013;10:1473-91
26. Ek CJ, Dziegielewska KM, Habgood MD, Saunders NR. Barriers in the developing brain and Neurotoxicology. Neurotoxicology 2012;33: 586-604
27. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 2008;325:349-56
28. Takashima T, Yokoyama C, Mizuma H, et al. Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir. J Nucl Med 2011;52:950-7
29. Vieux R, Hascoet JM, Merdariu D, Fresson J, Guillemin F. Glomerular filtration rate reference values in very preterm infants. Pediatrics 2010;125:e1186-92
30. Blake MJ, Castro L, Leeder JS, Kearns GL. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005;10:123-38
31. Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm 2013;452:3-7
32. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002;300: 355-60
33. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008;118:250-67
34. Yanni SB, Smith PB, Benjamin DK Jr, Augustijns PF, Thakker DR, Annaert PP. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos 2011;32:222-32
35. Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 2006;60:717-23
36. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 2013;54:11-27
37. Yanni SB, Annaert PP, Augustijns P, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos 2008;36:1119-25
38. Roka A, Melinda KT, Vasarhelyi B, Machay T, Azzopardi D, Szabo M. Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. Pediatrics 2008;121:e844-9
39. de Zwart L, Scholten M, Monbaliu JG, et al. The ontogeny of drug metabolizing enzymes and transporters in the rat. Reprod Toxicol 2008;26:220-30
40. Anderson BJ. Pharmacology in the very young: anaesthetic implications. Eur J Anaesthesiol 2012;29:261-70
41. Jadcherla SR, Berseth CL. Effect of erythromycin on gastroduodenal contractile activity in developing neonates. J Pediatr Gastroenterol Nutr 2002;34:16-22
42. Ali BH. Gentamicin nephrotoxicity in humans and animals: some recent research. Gen Pharmacol 1995;26:1477-87
43. Sokol PP, Huiatt KR, Holohan PD, Ross CR. Gentamicin and verapamil compete for a common transport mechanism in renal brush border membrane vesicles. J Pharmacol Exp Ther 1989;251:937-42
44. Dutt A, Priebe TS, Teeter LD, Kuo MT, Nelson JA. Postnatal development of organic cation transport and mdr gene expression in mouse kidney. J Pharmacol Exp Ther 1992;261:1222-30
45. Rose K, Della Pasqua O. Development of paediatric medicines: concepts and principles. Handb Exp Pharmacol 2011;205:111-24
46. Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World Health Organ 2011;89:46-53
47. McBeth CL, McDonald RJ, Hodge MB. Antibiotic sampling from central venous catheters versus peripheral veins. Pediatr Nurs 2004;30:200-2
48. Ramasethu J. Complications of vascular catheters in the neonatal intensive care unit. Clin Perinatol 2008;35:199-222, x
49. Food and Drug Administration. Guidance for industry-Population pharmacokinetics, 1999. http://www.fda.gov/downloads/Drugs/../Guidances/UCM072137.pdf. Accessed 09 June 2014
50. Cohen-Wolkowiez M, Ouellet D, Smith PB, et al. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother 2012;56:1828-37
51. Wade KC, Wu D, Kaufman DA, et al.; National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008;52:4043-9
52. Cohen-Wolkowiez M, Benjamin DK Jr, Ross A, et al. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit 2012;34:312-9
53. Cohen-Wolkowiez M, Sampson M, Bloom BT, et al.; Best Pharmaceuticals for Children Act-Pediatric Trials Network. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J 2013;32:956-61
54. Suyagh M, Collier PS, Millership JS, et al. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 2011;127:e367-74
55. Patel P, Mulla H, Kairamkonda V, et al. Dried blood spots and sparse sampling: A practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. Br J Clin Pharmacol 2013;75:805-13
56. Cohen-Wolkowiez M, Watt KM, Hornik CP, Benjamin DK Jr, Smith PB. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J 2012;31:935-7
57. Bell MJ, Shackelford P, Smith R, Schroeder K. Pharmacokinetics of clindamycin phosphate in the first year of life. J Pediatr 1984;105:482-6
58. Koren G, Zarfin Y, Maresky D, Spiro TE, MacLeod SM. Pharmacokinetics of intravenous clindamycin in newborn infants. Pediatr Pharmacol (New York) 1986;5:287-92
59. Li Z, Chen Y, Li Q, et al. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants. Eur J Clin Pharmacol 2013;69:1223-33
60. Cohen-Wolkowiez M, Watt KM, Zhou C, et al. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. Antimicrob Agents Chemother 2014;58:2856-65
61. van Enk JG, Touw DJ, Lafeber HN. Pharmacokinetics of meropenem in preterm neonates. Ther Drug Monit 2001;23:198-201
62. Bradley JS, Sauberan JB, Ambrose PG, Bhavnani SM, Rasmussen MR, Capparelli EV. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J 2008;27:794-9
63. van den Anker JN, Pokorna P, Kinzig-Schippers M, et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother 2009;53:3871-9
64. Smith PB, Cohen-Wolkowiez M, Castro LM, et al.; Meropenem Study Team. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J 2011;30:844-9
65. Padari H, Metsvaht T, Korgvee LT, et al. Short versus long infusion of meropenem in very-low-birth-weight neonates. Antimicrob Agents Chemother 2012;56:4760-4
66. Cohen-Wolkowiez M, Poindexter B, Bidegain M, et al.; Meropenem Study Team. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis 2012;55: 1495-502
67. Pfizer Labs, Division of Pfizer Inc. Metronidazole injection, solution, 2010. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9db2ddc3-8193-4efc-bd39-f532ccec47c5. Accessed 09 June 2014
68. Cardinal Health. Piperacillin and tazobactam (piperacillin sodium, tazobactam sodium) injection, powder, for solution, 2013. http://dailymed. nlm.nih.gov/dailymed/lookup.cfm?setid=7b687747-bf51-4366-9277-29bc82fc665a. Accesssed 09 June 2014
69. AstraZeneca Pharmaceuticals, LP. Merrem IV (meropenem) injection, 2013. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c15e88d3-d903-4e7a-f683-e29f51afa848. Accessed 09 June 2014
70. Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010;87:93-9
71. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25:1110-5
72. Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010;54:2633-7
73. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009; 28:412-5
74. Astellas Pharma US, Inc. Mycamine (micafungin sodium) injection, powder, lyophilized, for solution, 2013. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a064c4a7-25ec-4a2c-afc2-703491a4a38b. Accessed 09 June 2014
75. Watt K, Manzoni P, Cohen-Wolkowiez M, et al. Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab 2013;14:193-202
76. Turner K, Manzoni P, Benjamin DK, Cohen-Wolkowiez M, Smith PB, Laughon MM. Fluconazole pharmacokinetics and safety in premature infants. Curr Med Chem 2012;19:4617-20
77. Wade KC, Benjamin DK Jr, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009;28:717-23
78. Piper L, Smith PB, Hornik CP, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J 2011;30:375-8
79. Watterberg K. Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. Clin Perinatol 2012;39:47-59
80. Patel P, Tanna S, Mulla H, Kairamkonda V, Pandya H, Lawson G. Dexamethasone quantification in dried blood spot samples using LC-MS: The potential for application to neonatal pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:3277-82.